Molecular diagnostics company Genedrive premiered its Genedrive hepatitis C virus (HCV) ID kit at the MEDLAB Asia Pacific Exhibition & Congress in Singapore.
The qualitative HCV assay is marketed as ‘an accurate and cost-effective molecular solution for HCV testing’. It provides results within 90 minutes and does not require viral RNA extraction as it only requires a patient’s plasma. The assay is a potential solution for low-throughput, decentralised laboratories and is designed for use in this environment.
Genedrive chief executive David Budd said: “The Genedrive HCV ID Kit is being presented to key opinion leaders and distribution partners at company’s booth M19.
“With the advent of new curative direct acting antiviral treatments for HCV, we believe that there is a major opportunity to support tackling the global burden of the disease if accurate, decentralised diagnostics can be used to identify those living with HCV and give them access to therapy.”
The test kit has been created to support the increasing number of direct-acting antiviral treatments in low and middle income countries.
Traditional diagnostic tests for HCV are complex and this means they are often only used in specialised hospital laboratories. Modern direct acting antiviral agents have led to the diagnostic algorithm being simplified and treatment can now be administered immediately following the positive detection of HCV RNA.
Decentralised molecular diagnostics could make HCV testing widely available and provide rapid identification of patients that could benefit from these treatments.
The Genedrive HCV ID test is performed on the company’s portable molecular diagnostics platform.
Over 4,000 medical technology delegates from around the world are attending MEDLAB to showcase and explore their technologies and innovations in the field of laboratory diagnostics. The congress showcases products in many areas including point of need and infectious diseases.